People with Lung Cancer, Like Others with Serious Underlying Medical Conditions
Might Be at an Increased Risk for Severe Illness from COVID-19

Lung cancer is the second most common cancer in both men and women. This year, an estimated 228,820 adults (116,300 men and 112,520 women) in the United States will be diagnosed.

The fight against lung cancer continues with new research and scientific advances, including cancer experts investigating potential ways to treat the disease in earlier stages. Some of these latest findings in non-small cell lung cancer (NSCLC), including investigational studies in earlier stages of the disease, were presented at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program.

Roy S. Herbst, MD, PhD of Yale Cancer Center and Smilow Cancer Hospital talks on the latest news from ASCO in the fight against lung cancer.

Lung cancer makes up almost 25% of all cancer deaths. There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common type of lung cancer. In fact, about 80%-85% of lung cancer cases are NSCLC. About 40% of patients are diagnosed at a later stage of disease, such as Stage IV, when the cancer has progressed to other organs. Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC. The prevalence of EGFR mutations in early stage are estimated to be ~33% in a global NSCLC population.

Interview courtesy: AstraZeneca
for video and more info, go to http://goodnewsplanet.com/new-research-from-prominent-cancer-meeting-for-those-with-lung-cancer/
#roy #harbst #yale #cancer #center #smilow #covid-19 #covid #19 #covid19 #lung #severe #illness #medical #risk #diagnosed #research #scientific #advances #disease #cell #nsclc #american #society #clinical #oncology #asco #virtual #hospital #astrazeneca